TAVR linked to lower stroke risk than SAVR in patients with AS and cardiogenic shock
Transcatheter aortic valve replacement (TAVR) is associated with fewer in-hospital complications than surgical aortic valve replacement (SAVR) when patients present with aortic stenosis (AS) and cardiogenic shock (CS), according to new data being presented at SCAI 2024 Scientific Sessions, the annual meeting of the Society for Cardiovascular Angiography and Interventions (SCAI).
The study’s authors explored data from the National Inpatient Sample, tracking more than 13,000 patients hospitalized with AS and CS from 2016 to 2020 and treated with either isolated TAVR or isolated SAVR. While 38.6% of patients underwent TAVR, the other 61.4% underwent SAVR. TAVR patients were more likely to be 65 years old or older, female or present with renal failure, chronic pulmonary disease or a history of coronary artery bypass grafting or Impella support. SAVR patients, meanwhile, were more likely to be Black, Hispanic and present with peripheral artery disease.
Overall, TAVR was linked to lower rates of stroke, acute kidney injury and major bleeding events. As one may expect, length of stay and total costs were also lower among TAVR patients.
The odds of in-hospital mortality, pacemaker placement and vascular complications, on the other hand, were comparable between the two treatment options.
“Results show that TAVR is a more feasible and safe option when compared to SAVR for some of the most high-risk patients who have AS and CS,” lead author Mahmoud Ismayl, MD, an assistant professor with Mayo Clinic, said in a statement previewing his presentation. “We were initially able to see this in our clinical practice, so it is rewarding to share it with the cardiology community at this prestigious meeting. It is important that patients and cardiovascular professionals are aware of the benefits of the use of TAVR such as lower in-hospital complications and resource utilization because they are then able to advocate for the best treatment option.”
Click here for additional information about SCAI 2024 Scientific Sessions. Prior Cardiovascular Business coverage of the conference is available here and here.
Michael has more than 16 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.